Antabuse helps support alcohol abstinence by blocking the normal breakdown of alcohol’s toxic metabolite, acetaldehyde. It contains disulfiram and is intended for adults with alcohol dependence who…
Antabuse helps support alcohol abstinence by blocking the normal breakdown of alcohol’s toxic metabolite, acetaldehyde. It contains disulfiram and is intended for adults with alcohol dependence who have chosen to avoid drinking. Alcohol exposure during treatment can trigger a severe physical reaction, making adherence and clinical supervision essential.
Antabuse is an oral tablet containing disulfiram, a deterrent medicine used as part of treatment for alcohol dependence. Disulfiram is also described chemically as tetraethylthiuram disulfide and belongs to the alcohol-dependence treatment group identified by ATC code N07BB01.
Its purpose is to support continued abstinence rather than reduce intoxication, treat alcohol withdrawal, or remove alcohol cravings immediately. The treatment works best when combined with structured support, relapse-prevention planning, and follow-up for liver health and mental wellbeing.
Clinical guidance from NICE places disulfiram among medicines that may support abstinence when a person understands the risks and is committed to avoiding alcohol [1].
The tablets supplied for this product contain disulfiram at a stated strength of 400 mg, with 50 tablets in the pack.
After alcohol enters the body, alcohol dehydrogenase converts ethanol into acetaldehyde. Aldehyde dehydrogenase then breaks acetaldehyde down into less harmful compounds. Disulfiram blocks aldehyde dehydrogenase, so acetaldehyde can build up rapidly if alcohol is consumed.
That build-up causes the disulfiram–alcohol reaction. Symptoms may include facial flushing, throbbing headache, sweating, nausea, vomiting, chest discomfort, breathlessness, palpitations, low blood pressure, dizziness, and weakness. Severe reactions can involve collapse, abnormal heart rhythm, heart failure, seizures, or loss of consciousness.
The mechanism differs from medicines that reduce alcohol craving. Naltrexone acts on opioid receptors, while acamprosate influences glutamatergic and GABA-related signalling after abstinence has begun. Disulfiram instead creates a behavioural deterrent through alcohol metabolism.
The US FDA product information describes disulfiram’s aldehyde dehydrogenase inhibition and the possibility of a serious reaction after alcohol exposure [2].
Disulfiram does not neutralise ethanol in the stomach. It interferes later in the metabolic pathway, at the acetaldehyde stage. This explains why even a small quantity of alcohol may produce a disproportionate reaction.
Patients sometimes overlook alcohol in sauces, desserts, fermented products, cough mixtures, mouthwashes, aftershaves, hand sanitiser, and topical medicines. The risk depends on the amount and route of exposure, but deliberate testing with alcohol is unsafe.
The suitable dose differs between strengths and between users, so there is no single amount that suits everyone. Antabuse is taken orally as prescribed, with the dose selected by the prescriber according to treatment goals, tolerability, medical history, and the response to therapy.
Treatment commonly follows a supervised starting phase and a maintenance phase. Some patients take the medicine daily; supervised dosing can be considered when adherence is uncertain or when a treatment plan requires it. The tablet supplied for this product should be used only according to the prescribed regimen.
Key administration points include:
One common mistake is taking disulfiram in the morning and then using an alcohol-containing product later without connecting the two events. Another is assuming that no reaction means alcohol is safe. The reaction is unpredictable and may be severe.
Medicines for alcohol dependence have different treatment aims. The most suitable option depends on whether the main goal is complete abstinence, reduced heavy drinking, relapse prevention after detoxification, or control of craving.
| Treatment category | Main pharmacological role | Clinical focus |
|---|---|---|
| Disulfiram | Blocks aldehyde dehydrogenase and creates an alcohol reaction | Deterrence when abstinence is the agreed goal |
| Naltrexone | Reduces opioid-mediated reward from alcohol | Craving and heavy-drinking reduction |
| Acamprosate | Helps stabilise excitatory and inhibitory signalling after abstinence | Maintaining abstinence after detoxification |
Naltrexone may be unsuitable for someone using opioid pain medicines or with certain liver conditions. Acamprosate requires attention to kidney function and is usually used after abstinence has been established. Topiramate is sometimes used off-label, with possible cognitive, neurological, and metabolic adverse effects.
A clinician may change treatment when adherence is poor, liver or kidney results change, side effects become unacceptable, or the person’s treatment goal changes. Stopping one medicine and starting another needs an individual plan, especially when alcohol use, opioid medicines, anticoagulants, or liver disease are involved. Follow-up should confirm the treatment goal and review new symptoms. The plan should identify who to contact after a missed dose or alcohol exposure. Regular review can help match the medicine to changing clinical needs.
Several mistakes can reduce the benefit of Antabuse or increase risk:
A useful habit is to tell close family members about the alcohol warning, especially if supervised dosing forms part of the treatment plan. They should know that a reaction may require urgent medical help.
Antabuse is not suitable for everyone. Treatment requires an individual medical assessment, with attention to liver function, mental health, heart health, neurological history, and current medicines.
Pregnancy and breastfeeding require a careful risk assessment. Disulfiram should not be started casually during pregnancy, and breastfeeding decisions depend on the clinical circumstances and available alternatives.
People with diabetes, epilepsy, kidney disease, thyroid disorders, asthma, or peripheral neuropathy may need extra review. A history of liver disease does not automatically determine treatment, but it makes baseline assessment and follow-up more important.
Seek urgent medical help after alcohol exposure if there is chest pain, severe breathlessness, fainting, confusion, persistent vomiting, a very fast or irregular heartbeat, seizures, or collapse.
Disulfiram can cause side effects without alcohol exposure. Reported reactions include drowsiness, fatigue, headache, nausea, vomiting, abdominal discomfort, metallic or garlic-like taste, and skin rash. Some people experience reduced energy during the first part of treatment.
Neurological effects can include tingling, numbness, weakness, unsteady walking, confusion, or visual changes. Liver injury is an important medical concern. Symptoms such as persistent nausea, loss of appetite, dark urine, pale stools, yellowing of the skin or eyes, marked itching, or pain under the right ribs require urgent medical assessment.
A rash may be mild, but swelling of the lips or face, breathing difficulty, blistering skin, or widespread peeling requires emergency care. Drowsiness can impair driving, cycling, machinery use, and work requiring sustained attention.
The frequency of individual adverse effects varies between product information sources and patient populations. A person’s liver function, alcohol exposure, age, other medicines, and underlying illness can change the risk profile. The WHO alcohol-treatment framework supports monitoring for adverse effects and treatment complications during relapse-prevention care [3].
In clinical practice, doctors often find that disulfiram works best when the patient has a clear abstinence goal and understands that the medicine does not remove the underlying causes of alcohol dependence. The deterrent effect is practical, but it depends on taking the tablets consistently and avoiding alcohol-containing products.
A prescriber would usually discuss liver symptoms, medication interactions, mental health, and the person’s support network before treatment. Follow-up may include liver blood tests, review of side effects, alcohol-use assessment, and discussion of counselling or mutual-support options.
Doctors also distinguish a lapse from a treatment failure. Alcohol exposure needs prompt clinical advice because it can produce a medical emergency, while a return to drinking may require a broader review of withdrawal risk, home safety, depression, anxiety, and relapse triggers.
Chest pain, severe breathlessness, fainting, confusion, seizures, collapse, a very fast or irregular heartbeat, or repeated vomiting after alcohol exposure require emergency assessment. Yellow skin or eyes, dark urine, severe weakness, loss of appetite, or pain under the right ribs may indicate liver injury and need urgent medical review. The MHRA’s safety principles for adverse drug reactions support prompt assessment when serious or unexpected symptoms develop, including during 2026 clinical care.
Older adults may use disulfiram when a prescriber considers the treatment suitable, but age-related liver, kidney, neurological, and cardiovascular changes can alter tolerability. Drowsiness, unsteadiness, confusion, and falls deserve close attention, especially when other sedating medicines are used. Guidance from NICE, current in clinical practice during 2026, supports individual assessment and follow-up rather than an automatic age-based decision.
Disulfiram does not usually require a gradual taper because it is used for enzyme inhibition rather than physical replacement therapy. The alcohol reaction can remain possible for up to two weeks after the final dose, so alcohol avoidance must continue for the period specified by the prescriber. The EMA’s 2012 pharmacovigilance guidance supports review of persistent effects and interaction risks after treatment stops.
Alcohol should be avoided during treatment and for the post-treatment period advised by the prescriber. Exposure can occur through drinks, food ingredients, liquid medicines, mouthwash, cosmetics, and topical products, and the resulting reaction can include flushing, vomiting, low blood pressure, heart rhythm problems, or collapse. The FDA disulfiram product information continues to identify alcohol exposure as the central safety hazard in 2026 treatment planning.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
The firm alcohol rule helped me stop negotiating with myself. I felt tired at first and had a strange taste, but those problems became easier. I still needed counselling because the tablets did not deal with stress.
Derby Several months 26 Oct 2026The first weeks were manageable, although nausea made mornings unpleasant. I nearly used a medicinal mouthwash without thinking, so the alcohol warning became part of my daily routine. The treatment helped, but regular blood tests and family support mattered.
Luton Several weeks 30 Sept 2026I had increasing fatigue and loss of appetite after several weeks. My clinician arranged a review and stopped the treatment while my liver tests were checked. It had helped me avoid alcohol, but the side effects made continued use unsuitable.
Leicester Several weeks 14 Oct 2026
